TSO3 files with Health Canada for new faster and gentler cycles able to
sterilize general instruments, short and complex flexible endoscopes as well
as rigid channeled medical devices
Stock symbol:TSX: TOS Outstanding shares: 47,863,402
"Today we are filing an amendment with Health
The new STERIZONE(R) 125L+ Sterilizer offers three cycles in a single sterilizer and is able to meet healthcare sterilization demands that previously required two or more sterilization systems. This low temperature sterilization system offers speed, high throughput, increased instrument compatibility, and cost effective sterilization, while engineered to be customer safe and eco-friendly. The new cycles accommodate general surgical instruments, short as well as long rigid and flexible endoscopes including complex multi-channel devices.
"This improved standard comes at a time when customers are seeking solutions for their low temperature sterilization requirements", continued
Earlier in 2009, TSO3 outlined its plans to; increase the utility of its sterilizer though the creation of new cycles; develop relationships leading to a channel partner and increase market opportunities via expansion outside of
About TSO3
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE(R) 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.
In contrast to other methods, the ozone sterilization process developed and patented by TSO3 combines attributes that answer market needs for: efficacy, costs savings, increased safety for patients and hospital staff, and a "green" environmentally safe process.
The TSO3 STERIZONE(R) 125L Sterilizer is cleared for commercialization by the US and Canadian regulatory agencies for sterilization of metal and heat sensitive instruments, as well as for devices with diffusion-restricted spaces, such as rigid endoscopes having a single stainless steel channel. In 2009, the Company received clearance from Health
For more information about TSO3, visit the Company's Web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
For further information: For further information: Caroline Côté, Director, Corporate Communications and IR, (418) 651-0003, Ext. 237, [email protected]; Source: TSO3 Inc.
Share this article